Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NexHand Inc.

Precisely quantifying SUI severity and sling tension

This article was originally published in Start Up

Executive Summary

NexHand Inc. has developed proprietary, sensor-based "smart surgical glove" technology designed to enable physicians to assess the severity of stress urinary incontinence. Its technology has been developed into two disposable products: the first is a noninvasive diagnostic tool for assessing the severity of SUI in the clinical setting, the UroGlove, and the second is a probe-based sensor for determining proper tensioning of urethral slings during surgery.

You may also be interested in...



Medtech Start-Ups Innovate In Urinary Incontinence

Angel- and venture-backed medtech start-ups are working to fill the tremendous unmet need for alternative device options for treating (not just managing) female urinary incontinence a condition that has a significant impact on quality of life for millions of women. In this issue we profile Floelle, InControl Medical, NexHand, and Solace Therapeutics.

US FDA Offers Clarity On UV Filter Environmental Impact Statement, GRASE Implications

Federal law requiring agencies to weigh and document potential environmental impacts of major regulatory actions does not dictate what happens next. Neither does it provide federal agencies with authorities beyond their statutory purviews, FDA/CDER leadership says.

EU Joint Regulatory Assessment Project Bears Fruit In COVID-19

The European Medicines Agency has reported progress with a collaborative project that involves other regulators in its assessments of COVID-19 products, and with the EU Medicines for All initiative for evaluating products for non-EU markets.

Topics

UsernamePublicRestriction

Register

MT037769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel